Ophthalmology. Glaucoma · 2025
Effects of Melatonin Supplementation on Sleep Quality in Patients with Advanced Glaucoma: A Randomized, Double-Masked, Placebo-Controlled Crossover Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nogueira Priscilla F, Vallim Julia R S, Barboza Marcello N C, Andersen Monica L, Teixeira Sérgio H, Gracitelli Carolina P B, Paranhos Augusto
Аннотация
PURPOSE: To evaluate the effect of oral melatonin administration in patients with advanced glaucoma on sleep-wake cycle variables recorded by actigraphy on a single night and sleep quality assessed by specific questionnaires.
DESIGN: Prospective, randomized, parallel, crossover, double-masked therapeutic-type.
PARTICIPANTS: Sixty-four patients aged between 40 and 80 years, diagnosed with advanced primary open-angle glaucoma, were included.
METHODS: Participants received 5 mg of melatonin or placebo daily for 30 days, 1-week washout period; all assessments were repeated after each treatment phase. Subjective sleep was evaluated using the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS). Objective sleep parameters total sleep time (TST), wake after sleep onset (WASO), number of awakenings, and sleep efficiency (SE) were measured by actigraphy. Vision-related quality of life was assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Standardized ophthalmologic exams, visual field testing (Swedish Interactive Threshold Algorithm Standard 24-2), and OCT-based retinal nerve fiber layer analysis were also performed.
MAIN OUTCOME MEASURES: The primary outcomes were PSQI and actigraphy-measured SE. The secondary outcomes included TST, WASO, number of awakenings, ESS, and NEI VFQ-25 scores.
RESULTS: All 64 participants completed the study. No significant differences were found between melatonin and placebo for any sleep or quality of life outcomes. However, both groups showed improvements over time: PSQI scores decreased (-1.36 points; P < 0.001) and NEI VFQ-25 scores increased (+3.09 points; P < 0.001), indicating a temporal effect. Poor sleep quality (PSQI > 5) and reduced SE were associated with worse objective sleep parameters and lower vision-related quality of life. No carryover or sequence effects were observed, and melatonin did not significantly impact actigraphy measures such as TST, WASO, or number of awakenings.
CONCLUSIONS: Melatonin supplementation did not significantly improve sleep quality compared to a placebo in patients with advanced glaucoma, based on both subjective and objective measures. The improvements observed in the sleep questionnaires during the treatment phases suggest that patient perception may play a significant role in sleep-related outcomes, underscoring the importance of considering placebo effects in clinical trials.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
DESIGN: Prospective, randomized, parallel, crossover, double-masked therapeutic-type.
PARTICIPANTS: Sixty-four patients aged between 40 and 80 years, diagnosed with advanced primary open-angle glaucoma, were included.
METHODS: Participants received 5 mg of melatonin or placebo daily for 30 days, 1-week washout period; all assessments were repeated after each treatment phase. Subjective sleep was evaluated using the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS). Objective sleep parameters total sleep time (TST), wake after sleep onset (WASO), number of awakenings, and sleep efficiency (SE) were measured by actigraphy. Vision-related quality of life was assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Standardized ophthalmologic exams, visual field testing (Swedish Interactive Threshold Algorithm Standard 24-2), and OCT-based retinal nerve fiber layer analysis were also performed.
MAIN OUTCOME MEASURES: The primary outcomes were PSQI and actigraphy-measured SE. The secondary outcomes included TST, WASO, number of awakenings, ESS, and NEI VFQ-25 scores.
RESULTS: All 64 participants completed the study. No significant differences were found between melatonin and placebo for any sleep or quality of life outcomes. However, both groups showed improvements over time: PSQI scores decreased (-1.36 points; P < 0.001) and NEI VFQ-25 scores increased (+3.09 points; P < 0.001), indicating a temporal effect. Poor sleep quality (PSQI > 5) and reduced SE were associated with worse objective sleep parameters and lower vision-related quality of life. No carryover or sequence effects were observed, and melatonin did not significantly impact actigraphy measures such as TST, WASO, or number of awakenings.
CONCLUSIONS: Melatonin supplementation did not significantly improve sleep quality compared to a placebo in patients with advanced glaucoma, based on both subjective and objective measures. The improvements observed in the sleep questionnaires during the treatment phases suggest that patient perception may play a significant role in sleep-related outcomes, underscoring the importance of considering placebo effects in clinical trials.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Предметные рубрики MeSH
HumansMelatoninDouble-Blind MethodCross-Over StudiesMaleFemaleMiddle AgedAgedProspective StudiesSleep QualityAged, 80 and overAdultGlaucoma, Open-AngleQuality of LifeActigraphyIntraocular PressureSurveys and QuestionnairesVisual FieldsCentral Nervous System DepressantsAdministration, OralFollow-Up StudiesSleep